{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:37:34Z","timestamp":1792553854630,"version":"4.5.0"},"reference-count":55,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["26\u2010A\u20104"],"award-info":[{"award-number":["26\u2010A\u20104"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["27\u2010A\u20102"],"award-info":[{"award-number":["27\u2010A\u20102"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:p>\n                    B\u2010cell non\u2010Hodgkin lymphoma (B\u2010\n                    <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>\n                    ) is the most frequent hematological malignancy. Although refined chemotherapy regimens and several new therapeutics including rituximab, a chimeric anti\u2010\n                    <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                    20 monoclonal antibody, have improved its prognosis in recent decades, there are still a substantial number of patients with chemorefractory B\u2010\n                    <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>\n                    . Anti\u2010\n                    <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                    19 chimeric antigen receptor (\n                    <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>\n                    ) T\u2010cell therapy is expected to be an effective adoptive cell treatment and has the potential to overcome the chemorefractoriness of B\u2010cell leukemia and lymphoma. Recently, several clinical trials have shown remarkable efficacy of anti\u2010\n                    <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                    19\n                    <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>\n                    T\u2010cell therapy, not only in B\u2010acute lymphoblastic leukemia but also in B\u2010\n                    <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>\n                    . Nonetheless, there are several challenges to overcome before introduction into clinical practice, such as: (i) further refinement of the manufacturing process, (ii) further improvement of efficacy, (iii) finding the optimal infusion cell dose, (iv) optimization of lymphocyte\u2010depleting chemotherapy, (v) identification of the best\n                    <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>\n                    structure, and (vi) optimization of toxicity management including cytokine release syndrome, neurologic toxicity, and on\u2010target off\u2010tumor toxicity. Several ways to solve these problems are currently under study. In this review, we describe the updated clinical data regarding anti\u2010\n                    <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                    19\n                    <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>\n                    T\u2010cell therapy, with a focus on B\u2010\n                    <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>\n                    , and discuss the clinical implications and perspectives of\n                    <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>\n                    T\u2010cell therapy.\n                  <\/jats:p>","DOI":"10.1111\/cas.13239","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T13:21:14Z","timestamp":1489670474000},"page":"1109-1118","source":"Crossref","is-referenced-by-count":88,"title":["Clinical development of anti\u2010\n                    <scp>CD<\/scp>\n                    19 chimeric antigen receptor T\u2010cell therapy for B\u2010cell non\u2010Hodgkin lymphoma"],"prefix":"10.1111","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-8088","authenticated-orcid":false,"given":"Shinichi","family":"Makita","sequence":"first","affiliation":[{"name":"Department of Hematology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics and Exploratory Oncology Research and Clinical Trial Center National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Department of Hematology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.187"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.4049\/jimmunol.161.12.6604","article-title":"Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single\u2010chain Fv of an anti\u2010collagen antibody and Fc epsilonRI\u2010signaling gamma subunit","volume":"161","author":"Annenkov AE","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.1.182"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1999"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150291"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.46"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000153"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198910000-00008"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","article-title":"Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas [abstract]","volume":"126","author":"Schuster SJ","year":"2015","journal-title":"Blood"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood.V128.22.3026.3026","article-title":"Treatment with chimeric antigen receptor modified T cells directed against CD19 (CTL019) results in durable remissions in patients with relapsed or refractory diffuse large B cell lymphomas of germinal center and non\u2010germinal center origin, \u201cdouble hit\u201d diffuse large B cell lymphomas, and transformed follicular to diffuse large B cell lymphomas","volume":"128","author":"Schuster SJ","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1182\/blood.V128.22.1100.1100","article-title":"Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with poor prognosis, relapsed or refractory CD19 + follicular lymphoma: prolonged remissions relative to antecedent therapy","volume":"128","author":"Chong EA","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.LBA-6.LBA-6"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2016.120"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7516"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.247"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1852.1852"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-692046"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.999.999"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-476606"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622936"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26286"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.650.650"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPO4DS0GTLSOEI"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87366"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0231"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.262"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082742"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1089\/10430340460732463"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-545020"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.13239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.13239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T20:59:39Z","timestamp":1694293179000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.13239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/cas.13239"],"URL":"https:\/\/doi.org\/10.1111\/cas.13239","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]}}}